DE69329397D1 - Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons - Google Patents

Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons

Info

Publication number
DE69329397D1
DE69329397D1 DE69329397T DE69329397T DE69329397D1 DE 69329397 D1 DE69329397 D1 DE 69329397D1 DE 69329397 T DE69329397 T DE 69329397T DE 69329397 T DE69329397 T DE 69329397T DE 69329397 D1 DE69329397 D1 DE 69329397D1
Authority
DE
Germany
Prior art keywords
derivatives
stritial
neuron
promote
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69329397T
Other languages
English (en)
Other versions
DE69329397T2 (de
Inventor
Michael E Lewis
Nicola Neff
Jill Roberts-Lewis
Chikara Murakata
Hiromitsu Saito
Yuzuru Matsuda
James C Kauer
Marcie A Glicksman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE69329397D1 publication Critical patent/DE69329397D1/de
Publication of DE69329397T2 publication Critical patent/DE69329397T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69329397T 1992-07-24 1993-07-26 Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons Expired - Lifetime DE69329397T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92010292A 1992-07-24 1992-07-24

Publications (2)

Publication Number Publication Date
DE69329397D1 true DE69329397D1 (de) 2000-10-12
DE69329397T2 DE69329397T2 (de) 2001-03-15

Family

ID=25443161

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69329397T Expired - Lifetime DE69329397T2 (de) 1992-07-24 1993-07-26 Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons
DE69310178T Expired - Lifetime DE69310178T2 (de) 1992-07-24 1993-07-26 K-252a DERIVATE
DE69333874T Expired - Lifetime DE69333874T2 (de) 1992-07-24 1993-07-26 Verwendung von vier K-252a Derivaten

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69310178T Expired - Lifetime DE69310178T2 (de) 1992-07-24 1993-07-26 K-252a DERIVATE
DE69333874T Expired - Lifetime DE69333874T2 (de) 1992-07-24 1993-07-26 Verwendung von vier K-252a Derivaten

Country Status (18)

Country Link
US (1) US5461146A (de)
EP (4) EP0768312B1 (de)
JP (3) JP3762427B2 (de)
KR (1) KR100276008B1 (de)
AT (3) ATE152111T1 (de)
AU (1) AU675236B2 (de)
BR (1) BR9306789A (de)
CA (1) CA2140924A1 (de)
DE (3) DE69329397T2 (de)
DK (3) DK0651754T3 (de)
ES (3) ES2151629T3 (de)
GR (2) GR3023817T3 (de)
HK (1) HK1028206A1 (de)
HU (5) HU225341B1 (de)
NO (2) NO305481B1 (de)
NZ (2) NZ254662A (de)
PT (1) PT768312E (de)
WO (1) WO1994002488A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
EP0699204B1 (de) * 1993-05-28 1998-04-15 Cephalon, Inc. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
KR100340159B1 (ko) * 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
DE69418978T2 (de) * 1993-12-07 1999-10-28 Lilly Co Eli Synthese von Bisindolylmaleimiden
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
ATE456367T1 (de) * 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
KR100464907B1 (ko) * 1994-10-26 2005-07-04 세파론, 인코포레이티드 신경계질환치료용단백질키나아제억제제
US5686444A (en) 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
AU2819397A (en) * 1996-05-07 1997-11-26 Presidents And Fellows Of Harvard College Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) * 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
ES2184106T3 (es) 1996-06-25 2003-04-01 Cephalon Inc Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
EP1011648B2 (de) * 1997-08-15 2005-07-20 Cephalon, Inc. Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
ES2194385T3 (es) 1997-12-31 2003-11-16 Cephalon Inc Derivados del k-252a 3'-epimeros.
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
ES2288042T3 (es) 1998-09-25 2007-12-16 Cephalon, Inc. Uso de pirrolocarbazoles condensados para prevenir/tratar daños de las celulas ciliadas sensoriales y neuronas cocleares.
MXPA01003761A (es) * 1998-10-13 2003-07-21 Kyowa Hakko Kogyo Kk Agente para tratar oftalmopatia.
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6323215B1 (en) 1999-07-09 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
BR0012327A (pt) 1999-07-09 2002-07-02 Ortho Mcneil Pharm Inc Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
AU2576501A (en) * 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
AU2001278084A1 (en) * 2000-07-31 2002-02-13 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
DE10113513A1 (de) * 2001-03-20 2002-10-02 Medinnova Ges Med Innovationen Kombinationspräparat zur Prophylaxe und/oder Therapie von Nervenzell- und/oder Gliazellschäden durch ein neues Behandlungsverfahren
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
US20050130877A1 (en) * 2003-03-14 2005-06-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitors
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
EP2305265A1 (de) 2003-08-08 2011-04-06 Novartis AG Kombinationen mit Staurosporinen
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
JP5442198B2 (ja) * 2004-02-27 2014-03-12 セファロン インコーポレイテッド 医薬化合物の結晶形
CN103251953A (zh) * 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
CN100513850C (zh) * 2005-08-23 2009-07-15 浙江华夏阀门有限公司 三角截面密封套
DK1919979T4 (en) * 2005-08-25 2017-07-17 Creabilis Therapeutics Spa Polymer conjugates of K-252A and derivatives thereof
JP2009508868A (ja) 2005-09-16 2009-03-05 シェーリング コーポレイション テモゾロミドおよびプロテインキナーゼインヒビターを用いる薬学的組成物および方法
WO2007042286A1 (en) 2005-10-11 2007-04-19 Merck Patent Gmbh Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof
WO2008130921A1 (en) * 2007-04-16 2008-10-30 Modgene, Llc Methods and compositions for diagnosis and treatment of depression and anxiety
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
CA2891855A1 (en) 2012-12-21 2014-06-26 Sykehuset Sorlandet Hf Egfr targeted therapy of neurological disorders and pain
EP3706735A1 (de) * 2017-11-06 2020-09-16 Snap Bio, Inc. Pim-kinaseinhibitorzusammensetzungen, verfahren und ihre verwendungen
WO2024018245A1 (en) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of calpain inhibitors for the treatment of the diabetic kidney disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) * 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62102388A (ja) * 1985-10-29 1987-05-12 Toppan Printing Co Ltd Ｉｃカ−ド
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
EP0303697B1 (de) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivate des physiologisch aktiven mittels k-252
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
IE921315A1 (en) * 1991-07-03 1993-01-13 Regeneron Pharma Method and assay system for neurothrophin activity
DE4133605C2 (de) * 1991-10-10 1994-05-11 Siemens Ag Flexibler Roboterarm
AU3064992A (en) * 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung

Also Published As

Publication number Publication date
NO307446B1 (no) 2000-04-10
EP0651754A4 (de) 1995-08-09
NO305481B1 (no) 1999-06-07
PT768312E (pt) 2001-03-30
EP1002534B1 (de) 2005-09-21
JP2003113184A (ja) 2003-04-18
ATE152111T1 (de) 1997-05-15
EP0651754B1 (de) 1997-04-23
DE69329397T2 (de) 2001-03-15
ES2101331T3 (es) 1997-07-01
US5461146A (en) 1995-10-24
EP0768312B1 (de) 2000-09-06
AU675236B2 (en) 1997-01-30
HUT71239A (en) 1995-11-28
NO950242D0 (no) 1995-01-23
ATE196142T1 (de) 2000-09-15
HU225341B1 (en) 2006-10-28
GR3034917T3 (en) 2001-02-28
EP0768312A2 (de) 1997-04-16
HU0301425D0 (en) 2003-07-28
JP3762427B2 (ja) 2006-04-05
EP1002534A1 (de) 2000-05-24
HU225297B1 (en) 2006-09-28
DK0651754T3 (da) 1997-10-27
HU9500192D0 (en) 1995-03-28
BR9306789A (pt) 1998-12-08
JPH08501080A (ja) 1996-02-06
NZ286198A (en) 2001-06-29
NO990542D0 (no) 1999-02-05
GR3023817T3 (en) 1997-09-30
NO950242L (no) 1995-03-07
EP1512688A1 (de) 2005-03-09
NZ254662A (en) 1996-11-26
DE69310178T2 (de) 1997-09-25
DE69333874D1 (de) 2006-02-02
DK0768312T3 (da) 2000-12-11
AU4688193A (en) 1994-02-14
EP0768312A3 (de) 1997-06-04
ATE304848T1 (de) 2005-10-15
HU0301601D0 (en) 2003-08-28
HU225342B1 (en) 2006-10-28
NO990542L (no) 1999-02-05
EP0651754A1 (de) 1995-05-10
HK1028206A1 (en) 2001-02-09
DE69333874T2 (de) 2006-05-04
JP3723533B2 (ja) 2005-12-07
KR950702564A (ko) 1995-07-29
DE69310178D1 (de) 1997-05-28
ES2248950T3 (es) 2006-03-16
KR100276008B1 (ko) 2000-12-15
DK1002534T3 (da) 2006-01-23
CA2140924A1 (en) 1994-01-25
ES2151629T3 (es) 2001-01-01
JP2005170955A (ja) 2005-06-30
WO1994002488A1 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
DE69329397D1 (de) Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons
BR8902533A (pt) Processo e aparelho para o tratamento de lama de despejo de tinta
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ES2062303T3 (es) Agentes antipsicoticos espirociclicos.
BR8804188A (pt) Processo para controlar a aspereza da superficie de um filme
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
SE9502893D0 (sv) Användning av kollagenas
IT8848251A0 (it) Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
DE69127940D1 (de) Vorrichtung zum Begrenzen des Einschlagwinkels von Fahrzeugrädern
FI883759A (fi) C.12-modifierade etromycin a-derivat.
DE69208008D1 (de) Verfahren zur Herstellung von 2-Amino-5,6-Dimethoxy Tetralin
FI896181A0 (fi) Menetelmä Ti02-pigmenttien valmistamiseksi
DE68906248D1 (de) Antagonisten fuer den platelet-aktivierungsfaktor, phomactine genannt, ihre herstellung und verwendung.
FR2659255B1 (fr) Procede de traitement de regeneration de sable de fonderie usage lie principalement a l'argile.
FR2640154B1 (fr) Jouet de puericulture en forme de vehicule pour l'apprentissage de la marche
DE69404370D1 (de) Gelatinase A zur Behandlung von der Alzheimerschen Krankheit
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
FR2629474B1 (fr) Procede d'electrosynthese de cetones benzyliques
BR9204370A (pt) Processo de descurtimento de recíduos de couro
IT8841610A0 (it) Mezzi e metodo per l'ottimizzazione dei processi produttivi.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition